BioSpace News Archive

SYNAPS Dx (SDx) is pleased to announce that with the acceptance of an oral presentation of “Autopsy-Confirmed Minimally Invasive Biomarker Identifies Alzheimer’s Disease Even in the Presence of Co-Morbid Pathologies” and a poster presentation of “Physicians’ Assessment of the Clinical Utility of a Novel Test to Diagnose Alzheimer’s Disease (AD),” the Company will participate at BRAINWeek 2023.

Organon announced the appointment of Juan Camilo Arjona Ferreira, M.D., as Chief Medical Officer and Charlotte Owens, M.D., as Head of Medical Affairs and Outcomes Research, strengthening the company’s global clinical and medical capabilities, advancing external relationships and fueling efforts to bring forward innovations to solve unmet health needs.

Ozette Technologies, Inc., a technology-driven life sciences company, today announced its partnership with Bloodworks Northwest, an independent, non-profit organization committed to saving lives through research

The global newborn eye imaging systems market is estimated to surpass around USD 441.42 million by 2032 up from USD 277.64 million in 2022, growing at a CAGR of 4.6% from 2023 to 2032.

Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today entered into an amendment to the company’s senior secured credit agreement with BMO as agent and lender.

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the “Company” or “Sona”) is pleased to announce it has partnered with EXCITE International (“EXCITE”), a global network of senior specialist physicians

BioGenCell, a leader in personalized cell therapy solutions and Westchester Medical Center, the academic affiliate of Touro University/New York Medical College have announced the launch of BioGenCell’s fourth Phase II clinical trial site in the United States.

Phanes Therapeutics, Inc. announced that it has formed a Clinical Advisory Board to enhance the development of its three clinical stage programs: PT199 for solid tumors, PT886 for gastric, gastroesophageal junction and pancreatic adenocarcinomas, and PT217 for small cell lung cancer and other neuroendocrine cancers.

NextCure, Inc. (Nasdaq: NXTC) today announced the presentation of preclinical data demonstrating that treatment with NC605, a novel anti-Siglec-15 (S15) antibody, reduced bone loss and enhanced bone formation and quality following immobilization in an experimental animal model of acute spinal cord injury (SCI), at the 2023 Military Health System Research Symposium (MHSRS).

TRACON Pharmaceuticals, Inc. (Nasdaq: TCON) announced today that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will participate at the following upcoming investor conferences and provide a company overview: